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4 hours after 90Y/177Lu-DOTATATE. Additionally phantom 
studies were performer to analyze the spatial resolution of 
different protocols.
RESULTS: Out of all the patients, median OS was 49.8 
months and median EFS time 24.3 months. Spatial resolution 
achieved for 90Y, 177Lu and PET imaging of 90Y component 
measured using the phantom of the torso filled up with water 
was 20 mm, 8mm and 4–5 mm FWHM, respectively. Spatial 
resolution in human body in our study was about 30 mm for 
90Y, 15 mm for 177Lu and 25–30 mm for PET imaging of 
90Y component.
CONCLUSIONS: The theoretically best spatial resolution of-
fers PET scanner, however it is important to keep in mind that 
90Y-imaging PET is not used for diagnosis purposes (small ac-
tivities) but rather to present new possibility of post- therapeutic 
imaging (substantially higher activities).
For post-therapeutic imaging after intravenous radiopharmaceu-
tical administration the best spatial resolution offers standard 
scintigraphic camera for 90Y/177Lu DOTATATE imaging, with 
using 177Lu photopeaks.
The worst spatial resolution offers standard scintigraphic camera 
for 90Y/177Lu DOTATATE imaging, with using 90Y bremsstrah-
lung gammas.
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Background
Neuroendocrine tumors (NETs) are a heterogeneous group 
of neoplasms derived from endocrine stem cells. The choice of 
an appropriate treatment option as far as patients with inoperable or 
metastatic neuroendocrine tumors are concerned, is limited. These 
tumors are characterized by overexpression of somatostatin recep-
tors (SSTR), which is utilized for imaging using SSTR analogs [1]. 
Knowledge of overexpression of somatostatin analogs leads to 
possibility to use it in diagnosis and radiolabeled therapy. Peptide 
receptor radionuclide therapy (PRRT) somatostatin analogs labeled 
with 90Y and 177Lu in neuroendocrine tumors (NETs) results in 
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symptomatic improvement, prolonged survival, and enhanced 
quality of life [2–5]. The post-therapeutic imaging leads to pos-
sibility to assess the biodistribution of radiopharmaceuticals. The 
information is useful for control of treatment, evaluation of dosimetric 
data or prediction of treatment effects. Such possibility is given by 
177Lu fraction of gamma emission. Moreover, 90Y is almost pure 
beta-emitter (99,999% b-) [6], so possibility of post-therapeutic 
imaging is already widely used in order to qualitatively assess bio-
distribution using bremsstrahlung. 
Several studies have reported on the use of high-resolution 90Y 
PET/CT scans in the evaluation of the biodistribution of 90Y-labeled 
glass or resin based microspheres after radioembolisation of malig-
nant liver lesions [7–11], but there are no data concerning this method 
in evaluation of radiopharmaceutics in other treatment procedures.
The aim of our study was to describe different possibility in 
post-therapeutic imaging in patients underwent tandem therapy 
90Y/177Lu- DOTATATE with preliminary results of 90Y PET imaging.
Material and methods
The study was approved by the ethical committee of Medical 
University of Warsaw. All patients gave written informed consent.
Patients
Thirty patients with histological conﬁ rmation of metastatic neu-
roendocrine tumors (G1 and G2) were treated with tandem therapy 
90Y/177Lu-DOTATATE.
The treated group consisted of 11 men and 19 women; the 
mean age was (± SD): 55 ± 10.9 y (range 39–73). Progressive 
disease, conﬁ rmed by CT and increased blood concentrations of 
chromogranin A (CgA) were present in both groups.
The response to the treatment was observed in CT and deﬁ ned 
according to the Response Evaluation Criteria in Solid Tumors (RE-
CIST criteria). 
The following inclusion criteria to the therapy were used:
— somatostatin receptor imaging (99mTc-HYNIC-TATE or 
68Ga-DOTATATE) positive uptake in the tumor and metasta-
ses at least 3 months before inclusion (qualitative analysis);
— histological conﬁ rmation of NET tumor, assessed as inoperable 
or as metastatic;
— hemoglobin level (Hb) ≥ 10 g/dL; Leucocytes (WBC) ≥ 2*109/L; 
thrombocytes (PLT) ≥ 90*109/L; 
— calculated glomerular ﬁ ltration rate (GFR) > 40 mL/min; 
— Karnofsky Performance Status ≥ 60; 
— life expectancy > 3 months; 
— no pregnancy or lactation. 
In patients receiving long-acting somatostatin analogs, 
therapy with somatostatin radiolabeled analogs was performed 
5 weeks after completion of therapy with octreotide (Sandostatin 
LAR; Novartis) and after 3–5 weeks with lanreotide (Somatuline; 
Somatuline autogel, Ipsen). The interval between chemotherapy 
and PRRT was at least 3 months. 
Treatment
Therapy was performed on an out-patients basis. 
Treatment sessions were repeated, up to a total calculated 
dose of 7.4 GBq/m2. The injected activity per one course equaled 
2.2–3.7 GBq. 
Regarding 90Y/177Lu-DOTATATE, 50% of the activity was at-
tributed to 90Y-DOTATATE and 50% to 177Lu-DOTATATE. Median 
period between the treatment courses was 49 days, respectively. 
A mixed amino-acid (1000 mL Vamin 18, Fresenius Kabi or Ami-
nomel 12,E, Baxter) and Ringer’s solutions (500 mL) were infused 
over 8 hours for kidney protection; with infusion of 200 mL prior 
to administration of the treatment [12]. Before administration of 
radiopharmaceutical, ondansetron (8 mg, Zofran , Glaxo Wellcome, 
Atossa, Anpharm S. A.) had been injected intravenously to prevent 
nausea and vomiting.
Post-therapy imaging
According to the physical properties of 90Y and 177Lu for 
imaging following points are important:
— 90Y is a beta-minus emitter with two decay modes: main with 
an end-point energy of 2.28 MeV and mean energy 0.93 MeV 
leading to the 90Zr ground state (99.99%) and rare one with 
end-point mean of 0.52 MeV and average energy 0.20 MeV 
(0.011%) leading to the 90Zr excited state at 1.78 MeV, followed 
by pair creation, a half-life of 64h [6, 13, 14].
— 177Lu is a beta-minus emitter with an end-point energy of 0.498 
MeV and mean energy 0.93 MeV (78.6%), a half-life of 6.73 d 
and gammas emitter mainly with 112 keV (6.5%) and 208 keV 
(11%) photopeaks [13].
90Y could be imaged on a standard scintigraphic camera or 
PET scanner, as recent studies have shown [7, 11]. Both uses scin-
tillation phenomena for gamma ray detection. Beta-minus high 
energy particles can’t be detect directly but this devices may be 
used for imaging of distribution of beta-emitters via bremsstrahlung 
phenomena — gammas produced by the deceleration of a charged 
particle when deﬂ ected by another charged particle, typically 
an electron by an atomic nucleus [15, 16]. For scintigraphic imaging 
whole body (WHBA) and single photon emission (SPECT) is used. 
For tandem 90Y/177Lu-DOTATATE therapy it is complicated to 
use spectrum gammas in standard scintigraphic camera. 
The components of spectrum are:
— gammas 112 keV and 208 keV photopeaks from 177Lu; 
— compton scattering gammas from 177Lu photopeaks;
— bremsstrahlung gammas from 177Lu, almost ﬂ at over 80–250 
keV energy range;
— bremsstrahlung gammas from 90Y, almost ﬂ at over 80–250 keV 
energy range.
Imaging possibilities of 90Y in PET scanner comes into exist-
ence in a very complex way — there are two subtle phenomena 
in the decay effecting with beta plus radiation. Firstly, very rarely 
(0.011%) 90Y decays to 90Zr ﬁ rst excited state that de-excite with 
pair production, from which positron annihilate producing pair of 
511 keV gammas. Secondly, bremsstrahlung gammas, emitted 
from 90Y beta-minus decay, with energy greater than 1.022 MeV 
can produce positron-electron pairs. Again, positron can annihilate 
with low-energy thermal electron, with result in two 511 keV gam-
mas. They may be used by PET scanner [15, 16].
RESULTS
Patients’ characteristics
The study included 30 patients with metastatic neuroendocrine 
tumors.
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This group consists of 15 patients with neuroendocrine 
foregut tumors, 9 with midgut neuroendocrine tumors, 1 patient 
with hindgut neuroendocrine tumors and 2 patients with other 
tumors (1 patient with Multiple Endocrine Neoplasia — MEN 1, 
1 patient with Hippel-Landau syndrome), and other 3 with unknown 
primary tumors. 
Results of therapy
All patients presented progressive disease before 90Y/177Lu-
-DOTATATE therapy. 
Out of all the patients, median OS was 49.8 months and median 
EFS time 24.3 months. 
90Y/177Lu-DOTATATE has been well tolerated, with little 
acute toxicity — main concern is renal and hematologic function 
(renal grade 3 and 4 not observed, hematological grade 3 in 2% 
of patients).
Results of post-therapy imaging
According the literature and earlier study in our Department we 
implement following imaging protocols [5].
For imaging 177Lu component of 90Y/177Lu-DOTATATE 
tandem with scintigraphic camera the 177Lu photopeaks are 
used. WHBA scan and SPECT acquisition of the abdomen were 
performed 24 hours post therapy injection, using the dual-head 
Varicam camera (ELSCINT). Acquisition was made with energy win-
dow ± 10% centered on 208 keV, with a parallel-hole, high-energy, 
general-purpose collimators. In case of WHBA continuous ac-
quisition parameters are: 256 × 256 matrix, 8 cm/min. In case of 
SPECT acquisition parameters are: 128 × 128 matrix, zoom 1.28, 
60 × 6° × 60 sec, iterative OSEM 2D reconstruction with Chang 
attenuation correction method and Gauss 6mm ﬁ lter.
In case post-therapeutic imaging with 90Y/177Lu DOTATATE 
tandem, acquisition protocol is fully exploiting abilities of the con-
temporary scintigraphic camera. 
Spatial resolution achieved in these conditions, measured 
using the phantom of the torso ﬁ lled up with water, is not worse 
than 8 mm FWHM. In our study spatial resolution in human body 
was about 15 mm.
For imaging 90Y component of 90Y/177Lu-DOTATATE tan-
dem with scintigraphic camera the bremsstrahlung phenomena 
was used. Imaging was performed 24 hours post-therapy us-
ing the dual-head Varicam camera (ELSCINT). Energy window 
was centered on 100 keV ± 35% window width, and with a paral-
lel-hole, low-energy, high resolution collimators. WHBA scans in 
256 × 256 matrix, 8 cm/min was performed. 
Spatial resolution achieved in these conditions, measured with 
using the phantom of the torso ﬁ lled up with water, is not worse 
than 20 mm FWHM. In our study spatial resolution in human body 
was highly depending on localization of metastasis in liver — for 
peripheral regions 25 mm and for hilum of liver 35–40 mm.
For imaging 90Y component of 90Y/177Lu-DOTATATE tan-
dem with PET scanner an attempt of acquisition was made. Data 
were acquired on Siemens Biograph Truepoint PET/CT (window 
511 keV ± 15%) 4 hours after 90Y/177Lu-DOTATATE administration. 
30 min PET scanning (one bed position centered on the liver) with 
low dose CT was performed for attenuation correction. The PET 
data were reconstructed using a TRUEX algorithm (2 iterations, 
14 subsets) with 168 × 168 matrix.
Number of electron-positron pairs, which occurs, is very small 
compared to the number of b-particles emitted by 90Y (about 
32 × 10–6 511 keV gammas pairs for one b-particle in theory [6, 13]. 
In this experiment, despite the high activity (approximately 4 GBq) 
the number of recorded true coincidence events constituting the 
image is low, and amount about 100 per sec true coincidences in 
comparison about 106 per sec gammas collected by the detector. 
An important advantage is a possibility of obtaining a resolution 
of modern PET scanner. For Biograph 64 SIEMENS PET scanner 
it is about 5 mm FWHM. The resolution in our study was about 
25–30 mm. Figure 1 is shown post-therapeutic different imaging 
techniques of the evaluation of biodistribution 90Y/177Lu-DOTATATE.
Disscusion
In radioisotope therapy pure beta-emitting radionuclides are 
used to deliver an intense, local radiation dose to the target tissue. 
In the past 90Y imaging was limited to distribution of 90Y-labeled 
radiopharmaceuticals in spaces such as the abdominal ca -
vity and joints after local injections [17]. The spatial and energy 
dependence of bremsstrahlung production causes an inherent 
limitation in spatial resolution for bremsstrahlung imaging. While 
high-energy photons are created near the decay site, most 
low-energy bremsstrahlung photons are produced further from 
the 90Ydecay location. 
For imaging 90Y component of 90Y/177Lu-DOTATATE tan-
dem with scintigraphic camera the bremsstrahlung phenomena 
was used. Should to emphasize, that in this phenomena gam-
mas come into existence in tissues surrounding activity source. 
In the end meaning worsening the spatial resolution is taking 
place, in our cases the received spatial resolution was 30 mm. The 
bremsstrahlung phenomena was in the literature successfully used 
for loco-regional deposition of 90Y-radiopharmaceuticals [19, 20], 
but after intravenous application of 90Y-peptides due to low spatial 
resolution it is not used for dosimetry study. It should be noted 
that the diagnostic point of view image shows the bremsstrahlung 
gammas coming into existence in tissues surrounding the source 
of the radiation, which degrades the resolution slightly.
177Lu imaging component of 90Y/177Lu-DOTATATE tandem 
therapy with scintigraphic camera the 177Lu photopeaks were 
used. Energy window 208 keV ± 10% giving the following beneﬁ ts: 
—  in view of a large number of registered gammas signiﬁ cant 
shortening the time of performing the examination is possible. 
In the end also a plausibility of coming into existence of patient 
moving artifacts is decreasing;
— it is minimizing coming into existence of artifacts dating from 
Compton scattering;
— a participation is curbing bremsstrahlung phenomena in the 
presence beta-emitters 90Y and 177Lu, which is a reason for 
degradation the spatial resolution.
With the use of low-energy b-components emitted by 177Lu, 
not only post-treatment scans can be acquired, but individual dosi-
metric data can also be obtained. The absorbed radiation doses to 
dose-limiting organs such as the kidneys and bone marrow are 
calculated to better tailor the total cumulative activity that can be 
administered to the individual patient [18]. 
For imaging 90Y component of 90Y/177Lu-DOTATATE tandem 
with PET scanner an attempt of acquisition was made.
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Despite such low quantum efﬁ ciency reliably diagnostic ima-
ges was achieved. An important advantage is to obtain a four 
times better resolution with respect a resolution use in SPECT cam-
eras which is about 20 mm (see C and D in Figure 1). Theoretically it 
seems that in centers with a PET scanner the use of 90Y as a primary 
post-therapeutic imaging method should be considered. In our 
approach should be emphasized that the 90Y-labeled therapeutic 
agent was given intravascularly by the vein. Therefore PET/CT im-
aging can reveal not only the distribution of local activity, but also 
general systemic biodistribution of tracer, however because of low 
number of electron-positron pairs it is not possible to receive whole 
body image for acceptable time. Our study focused on liver imaging 
to determine whether this method of imaging provides measurable 
beneﬁ ts. In PET/CT imaging using the 90Y-labeled therapeutic agent 
should pay attention to the fact that the ratio of signal to noise ratio 
is small, because the image consists of a small number of true 
coincidence events. In the case of locally administered high acti-
vity of 90Y-labeled glass it could be expect high-resolution image, 
and thus a better quality of imaging [7–11]. Unfortunately in case 
of systemic administered activity, this resolution is 25–30 mm, be-
cause of lower energy deposited in the liver. On the literature data 
90Y-DOTATOC systemic administration did not permit to obtain 
suitable PET imaging, whereas 90Y-DOTATOC directly injected into 
the surgical cavity by locoregional route in glioma treatment provide 
excellent imaging both PET and SPECT techniques [21].
Conclusions
The theoretically best spatial resolution (about 5–6 mm FWHM 
in phantom but 25–30 mm in human body) offers PET scanner, 
however it is important to keep in mind that 90Y-imaging PET 
is not used for diagnosis purposes (small activities) but rather to 
present new possibility of post-therapeutic imaging (substantially 
higher activities).
The medium spatial resolution (about 8–10 mm FWHM in 
phantom and 15 mm in human body) offers standard scintigraphic 
camera for 90Y/177Lu DOTATATE imaging, with using 177Lu 
photopeaks.
The worst spatial resolution (about 20 mm FWHM in phantom 
and 30 mm in human body) offers standard scintigraphic camera 
for 90Y/177Lu DOTATATE imaging, with using 90Y bremsstrahlung 
gammas.
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